Verisk terminates AccuLynx acquisition due to FTC review delays and plans to redeem $1.50 billion in senior notes.
Quiver AI Summary
Verisk, a global data analytics provider, has announced the termination of its agreement to acquire AccuLynx due to the Federal Trade Commission's incomplete review of the transaction by the specified deadline. As part of this decision, Verisk will redeem $1.50 billion in senior notes related to the acquisition, as required by a special provision in the note terms. This redemption will result in a leverage ratio of 1.9 times LTM adjusted EBITDA as of September 30, 2025. Verisk’s CEO, Lee Shavel, reaffirmed the company's commitment to effective capital allocation and continued investment in growth opportunities. AccuLynx has claimed that the termination is invalid, to which Verisk intends to respond vigorously.
Potential Positives
- Verisk's decision to terminate the acquisition allows the company to avoid potential regulatory complications and uncertainties associated with the Federal Trade Commission's ongoing review.
- The redemption of $1.50 billion in senior notes demonstrates Verisk's commitment to managing its capital structure and reducing leverage, which can strengthen its financial position.
- Verisk retains $1.2 billion in capacity under its share repurchase authorization, indicating ongoing commitment to returning capital to shareholders.
- The company's leadership expresses confidence in achieving long-term growth targets, reaffirming its strategic direction and operational discipline.
Potential Negatives
- Verisk's termination of the acquisition agreement with AccuLynx may indicate regulatory challenges or antitrust concerns that could impact future mergers or acquisitions.
- AccuLynx's assertion that the termination is invalid introduces potential legal complications that could divert management's focus and resources.
- The need to redeem $1.50 billion in senior notes due to the failed acquisition may strain the company’s liquidity position and limit capital allocation flexibility.
FAQ
Why did Verisk terminate its agreement to purchase AccuLynx?
Verisk terminated the agreement due to the FTC not completing its review by the set deadline.
What financial actions is Verisk taking after the merger termination?
Verisk will redeem $1.50 billion of senior notes at 101% of their principal amount plus interest.
What is Verisk's leverage ratio as of September 30, 2025?
Pro forma for the notes redemption, Verisk's leverage would have been 1.9 times LTM adjusted EBITDA.
How does Verisk plan to allocate capital moving forward?
Verisk aims to balance organic investments with returning capital to shareholders through dividends and repurchases.
What is AccuLynx's response to the merger termination?
AccuLynx believes Verisk's termination is invalid and Verisk intends to defend against this claim.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$VRSK Insider Trading Activity
$VRSK insiders have traded $VRSK stock on the open market 18 times in the past 6 months. Of those trades, 4 have been purchases and 14 have been sales.
Here’s a breakdown of recent trading of $VRSK stock by insiders over the last 6 months:
- NICHOLAS DAFFAN (Chief Information Officer) has made 0 purchases and 3 sales selling 16,259 shares for an estimated $4,541,062.
- LEE SHAVEL (Chief Executive Officer) has made 0 purchases and 4 sales selling 4,400 shares for an estimated $1,070,377.
- ELIZABETH MANN (Chief Financial Officer) has made 0 purchases and 6 sales selling 1,800 shares for an estimated $451,608.
- CHRISTOPHER JOHN PERRY purchased 1,000 shares for an estimated $259,800
- JEFFREY J DAILEY purchased 500 shares for an estimated $108,515
- GREGORY HENDRICK purchased 500 shares for an estimated $108,070
- KATHY CARD BECKLES (Chief Legal Officer) sold 326 shares for an estimated $98,080
- SABRA R. PURTILL purchased 450 shares for an estimated $98,077
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$VRSK Revenue
$VRSK had revenues of $768.3M in Q3 2025. This is an increase of 5.93% from the same period in the prior year.
You can track VRSK financials on Quiver Quantitative's VRSK stock page.
$VRSK Congressional Stock Trading
Members of Congress have traded $VRSK stock 5 times in the past 6 months. Of those trades, 2 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $VRSK stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 11/18.
- REPRESENTATIVE JULIE JOHNSON sold up to $15,000 on 11/03.
- REPRESENTATIVE VAL T. HOYLE sold up to $15,000 on 09/23.
- REPRESENTATIVE LISA C. MCCLAIN has traded it 2 times. They made 1 purchase worth up to $15,000 on 08/04 and 1 sale worth up to $15,000 on 08/13.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$VRSK Hedge Fund Activity
We have seen 475 institutional investors add shares of $VRSK stock to their portfolio, and 576 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MASSACHUSETTS FINANCIAL SERVICES CO /MA/ removed 1,616,818 shares (-38.6%) from their portfolio in Q3 2025, for an estimated $406,645,895
- FMR LLC removed 1,288,012 shares (-22.9%) from their portfolio in Q3 2025, for an estimated $323,947,898
- D. E. SHAW & CO., INC. added 1,273,460 shares (+196.4%) to their portfolio in Q3 2025, for an estimated $320,287,924
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 1,066,659 shares (+66.1%) to their portfolio in Q3 2025, for an estimated $268,275,405
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 910,413 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $228,977,973
- NUVEEN, LLC removed 789,156 shares (-64.5%) from their portfolio in Q3 2025, for an estimated $198,480,625
- TD ASSET MANAGEMENT INC removed 694,908 shares (-51.8%) from their portfolio in Q3 2025, for an estimated $174,776,311
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$VRSK Analyst Ratings
Wall Street analysts have issued reports on $VRSK in the last several months. We have seen 6 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- Wells Fargo issued a "Overweight" rating on 10/30/2025
- Barclays issued a "Overweight" rating on 10/30/2025
- RBC Capital issued a "Outperform" rating on 10/30/2025
- JP Morgan issued a "Overweight" rating on 10/30/2025
- Rothschild & Co issued a "Sell" rating on 10/16/2025
- Seaport Global issued a "Buy" rating on 10/01/2025
- Wolfe Research issued a "Outperform" rating on 09/03/2025
To track analyst ratings and price targets for $VRSK, check out Quiver Quantitative's $VRSK forecast page.
$VRSK Price Targets
Multiple analysts have issued price targets for $VRSK recently. We have seen 12 analysts offer price targets for $VRSK in the last 6 months, with a median target of $272.5.
Here are some recent targets:
- Toni Kaplan from Morgan Stanley set a target price of $270.0 on 12/17/2025
- Manav Patnaik from Barclays set a target price of $275.0 on 10/30/2025
- Ashish Sabadra from RBC Capital set a target price of $250.0 on 10/30/2025
- Andre Benjamin from Goldman Sachs set a target price of $239.0 on 10/30/2025
- Andrew Steinerman from JP Morgan set a target price of $250.0 on 10/30/2025
- Jason Haas from Wells Fargo set a target price of $300.0 on 10/30/2025
- David Motemaden from Evercore ISI Group set a target price of $250.0 on 10/30/2025
Full Release
JERSEY CITY, N.J., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Verisk (Nasdaq: VRSK), a leading global data analytics and technology provider, announced today that it has terminated its definitive agreement to purchase AccuLynx. This decision follows the notification by the Federal Trade Commission (FTC) that it has not completed its review of the transaction by the December 26, 2025 termination date set forth in the agreement.
The Company also announced that it will redeem the $1.50 billion aggregate principal amount of senior notes that were issued in connection with the planned acquisition for a price equal to 101% of their principal amount plus accrued and unpaid interest to the redemption date. The redemption is required pursuant to a special mandatory redemption provision in the terms of the notes. Pro forma for the redemption of the notes, Verisk’s leverage at September 30, 2025 would have been 1.9 times LTM adjusted EBITDA. As of September 30, 2025, Verisk had $1.2 billion of capacity remaining under its share repurchase authorization.
Lee Shavel, president and CEO of Verisk, stated, “Verisk remains committed to our capital allocation discipline – balancing organic investment in our highest return on capital opportunities while returning capital to shareholders through dividend and repurchases. We continue to have confidence in our ability to deliver results in line with our long-term growth targets for this year, for 2026 and beyond.”
AccuLynx has notified Verisk that it believes Verisk’s termination of the merger agreement is invalid. Verisk strongly disagrees with this assertion and intends to vigorously defend against any such assertions.
###
About Verisk
Verisk (Nasdaq: VRSK) is a leading strategic data analytics and technology partner to the global insurance industry. It empowers clients to strengthen operating efficiency, improve underwriting and claims outcomes, combat fraud and make informed decisions about global risks, including climate change, catastrophic events, sustainability and political issues. Through advanced data analytics, software, scientific research and deep industry knowledge, Verisk helps build global resilience for individuals, communities and businesses. With teams across more than 20 countries, Verisk consistently earns certification by
Great Place to Work
and fosters an
inclusive culture
where all team members feel they belong. For more,
visit Verisk.com
and the
Verisk Newsroom
.
Forward-Looking Statements
This release contains forward-looking statements. These statements relate to future events or to future financial performance and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements. This includes, but is not limited to, statements regarding expectations of meeting long-term growth targets. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “expect,” “intend,” “plan,” “target,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” or “continue” or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements, because they involve known and unknown risks, uncertainties, and other factors that are, in some cases, beyond our control and that could materially affect actual results, levels of activity, performance. Other factors that could materially affect actual results, levels of activity, performance, or achievements can be found in our quarterly reports on Form 10-Q, annual reports on Form 10-K, and current reports on Form 8-K filed with the SEC. If any of these risks or uncertainties materialize or if our underlying assumptions prove to be incorrect, actual results may vary significantly from what we projected. Any forward-looking statement in this Current Report on 8-K reflects our current views with respect to future events and is subject to these and other risks, uncertainties, and assumptions relating to our operations, results of operations, growth strategy, and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, whether as a result of new information, future events, or otherwise.